June 30, 2016

# Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

## Company CEO to Present on Wednesday, July 13th at 2:00 pm ET

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 06/30/16 --

Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that CEO and President, Tim Miller, Ph.D., will be presenting for the company at Cantor Fitzgerald's 2nd Annual 2016 Healthcare Conference in New York City, Wednesday, July 13th, 2016 at 2:00 pm ET.

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: ***Cantor Fitzgerald's 2nd Annual Healthcare Conference***
Date: Wednesday, July 13th, 2016
Time: 2:00 pm ET
Location: Le Parker Meridien, NYC
Webcast Link: ***http://wsw.com/webcast/cantor4/abeo***

***About Cantor Fitzgerald's 2nd Annual Healthcare Conference:***

Cantor Fitzgerald 2nd Annual Healthcare Conference brings together an innovative group of executive management leaders from public and private companies for an in-depth discussion of the trends and developments affecting biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.

***About Abeona :***

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV-NAGLU) and ABO-102 (AAV-SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). The company is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9- based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com

*This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.*

Company and Media Contact:

Andre'a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com

Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com

Source: Abeona Therapeutics